Interferon-alpha therapy in atopic dermatitis.

Authors:
  • AHA Harto
    A Harto
  • ESE Sendagorta
    E Sendagorta
  • BCB M Czarnetzki
    B M Czarnetzki
  • ALA Ledo
    A Ledo

Abstract
Thirteen patients with a severe adult form of atopic dermatitis (AD) received 3.0 x 10(6) IU of recombinant interferon-alpha 2a (rIFN-alpha 2a) 3 times a week. A satisfactory response was obtained in 5 of them. Serum IgE levels in all 13 patients remained unchanged throughout the study. Flu-like symptoms were common, but clinical or laboratory adverse effects were otherwise slight. The moderately beneficial therapeutic effects observed in this study support a possible role for IFN-alpha in controlling immunologic deficiencies in atopic dermatitis.